Peer-Reviewed Publications

"Patients with in-transit melanoma metastases have comparable survival outcomes following isolated limb infusion or intralesional PV-10-A propensity score matched, single center study.",

Journal of Surgical Oncology, 119(6):717-727, May 2019

PMDID: 30644564

"T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model.",

PLoS One, 13(4):e0196033, Apr 2018

PMDID: 29694419

"Quality of life patient-reported outcomes for locally advanced cutaneous melanoma",

Melanoma Research, 28(2):134-142, Apr 2018

PMDID: 29261570

"Intralesional PV-10 for the treatment of in-transit melanoma metastases - Results of a prospective, non-randomized, single center study",

Journal of Surgical Oncology, 117(4):579-587, Mar 2018

PMDID: 29529343

"Results of a phase II, open-label, non-comparative study of intralesional PV-10 followed by radiotherapy for the treatment of in-transit or metastatic melanoma",

Journal of Surgical Oncology, 115(7):891-897, Jun 2017

PMDID: 28230241

"Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death",

Cell Death and Disease 8(2):e2584; Feb 2017

PMDID: 28151483

"Intralesional PV-10 for in-transit melanoma - A single-center experience.",

Journal of Surgical Oncology, 114(3):380-4, Sep 2016

PMDID: 27237868

"Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1.",

Oncotarget, 7(25):37893-37905, June 2016

PMDID: 27177220

"The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses",

Journal of Clinical & Cellular Immunology, (2015) 6(4):343, Jul 2015

PMDID: 26618054

"Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma",

Annals of Surgical Oncology, (7):2135-42, Oct 2014

PMDID: 25348780

"In vitro inhibition of human liver cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes by rose bengal: system-dependent effects on inhibitory potential",

Xenobiotica, 44(7):606-14, Jul 2014

PMDID: 24405273

"Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma",

Journal of Surgical Oncology, 109(4):314-9, Mar 2014

PMDID: 24510477

"Intralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast Cancer",

PLoS ONE, 8(7):e68561, Jul 2013

PMDID: 23874673

"Novel use of Rose Bengal (PV-10) in two cases of refractory scalp sarcoma",

ANZ Journal of Surgery, 83:1-2:93, Jan 2013

PMDID: 23350981

"A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series",

Melanoma Research, 20:48, Jan 2010

PMDID: 20009957

"Interference from rose bengal with total bilirubin measurement.",

Clinical Chemistry, 55(5):1040-1, May 2009

PMDID: 19264853

"Chemoablation of metastatic melanoma using intralesional Rose Bengal",

Melanoma Research, 18:405, Dec 2008

PMDID: 18830132

"Systemic Phototoxicity following Intralesional Rose Bengal for Subcutaneous Melanoma Metastases",

Dermatology, 2008;216:361-362, Feb 2008

PMDID: 18292654

"Topical Rose Bengal: Pre-Clinical Evaluation of Pharmacokinetics and Safety",

Lasers in Surgery and Medicine, 32(2):101-10, Nov 2003

PMDID: 12561042

"Imaging Photosensitizer Distribution and Pharmacology using Multiphoton Microscopy",

In "Functional Imaging and Optical Manipulation of Living Cells and Tissues".

SPIE, Paper 4622A-14, Jan 2002

SDLID: 872032

"Functional Imaging of Photosensitizers using Multiphoton Microscopy",

In "Multiphoton Microscopy in the Biomedical Sciences II".

SPIE, Paper 4620-29, Jan 2002

SDLID: 871867

"Treatment of murine cutaneous melanoma with near infrared light",

Photochemistry and Photobiology, 75(3):296-301, Mar 2002

PMDID: 11950096

Additional Peer-Reviewed Literature

"Potent in vitro and xenograft antitumor activity of a novel agent, PV-10, against relapsed and refractory neuroblastoma.",

OncoTargets and Therapy, 2019 Feb 18;12:1293-1307, Feb 2019

PMDID: 30863096

"Quality of life patient-reported outcomes for locally advanced cutaneous melanoma",

Melanoma Research, 28(2):134-142, Apr 2018

PMDID: 21111967

"What is the OPTiMal Way to Manage In-Transit Disease?",

Annals of Surgical Oncology, 23(13):4126-4129, Dec 2016

PMDID: 27380046

"Malignant melanoma - The cradle of anti-neoplastic immunotherapy",

Critical Reviews in Oncology/Hematology, 2016;106:25-54, Oct 2016

PMDID: 27637351

"ESMO World Congress on Gastrointestinal Cancer and European Post-Chicago Melanoma/Skin Cancer Meeting",

Pharmacy and Therapeutics, 2016;41(9):581-586, Sep 2016

PMDID: 27630529

"Rose bengal uptake by E. faecalis and F. nucleatum and light-mediated antibacterial activity measured by flow cytometry.",

Journal of Photochemistry and Photobiology B, 2016;162:258-265, Sep 2016

PMDID: 27394008

"The Role of Intralesional Therapies in Melanoma.",

Oncology, 30(5):436-41, May 2016

PMDID: 27188674

"Intralesional immunotherapy as a strategy to treat melanoma.",

Expert Opinion on Biological Therapy, 16(5):619-26, May 2016

PMDID: 26898656

"Intralesional therapy for advanced melanoma: promise and limitation",

Current Opinion in Oncology, 27(2):151-6, Mar 2015

PMDID: 25629369

"GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report",

Medicine, 2016;95(4):e2124-e2634, Jan 2016

PMDID: 26825879

"Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus",

Bioorganic & Medicinal Chemistry, 2015;23(21):7061-7068, Nov 2015

PMDID: 26432604

"The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options",

Cancers, 2015;7(3):1154-1177, Jul 2015

PMDID: 26140669

"Treatment of Metastatic Melanoma in an Immunodeficient Patient",

American Medical Student Research Journal, 2015;2(1):138-142, May 2015

AMSRJ: 2015:2(1)

"Intralesional therapy for in-transit and satellite metastases in melanoma.",

Surgical Oncology Clinics, 2015;24(2):299-308, Apr 2015

PMDID: 25769713

"Photo-induced inhibition of Alzheimer's β-amyloid aggregation in vitro by rose bengal",

Biomaterials, 2015;38:43-49, Jan 2015

PMDID: 25457982

"Intralesional therapy for metastatic melanoma",

Expert Opinion on Pharmacotherapy, 2014;15(18):2629-39, Dec 2014

PMDID: 25381015

"Rose Bengal suppresses gastric cancer cell proliferation via apoptosis and inhibits nitric oxide formation in macrophages.",

Journal of Immunotoxicology, 2014;11(4):367-75, Oct 2014

PMDID: 24575814

"Selective toxicity of rose bengal to ovarian cancer cells in vitro",

Int J Physiol Pathophysiol Pharmacol, 2012;4(2):99-107, Jun 2012

PMDID: 22837809

"Local and Intralesional Therapy of In-Transit Melanoma Mestasases",

Journal of Surgical Oncology, 2011;104:391-396, Sep 2011

PMDID: 21858834

"Current and Planned Multicenter Trials for Patients WIth Primary or Metastatic Melanoma",

Journal of Surgical Oncology, 2011;104:430-437, Sep 2011

PMDID: 21858839

"Intralesional agents in the management of cutaneous malignancy: a review.",

Journal of the American Academy of Dermatology, 64(2):413-22, Feb 2011

PMDID: 20334952

"American Society of Clinical Oncology, 2010 Annual Meeting and Rose Bengal: From a Wool Dye to a Cancer Therapy",

Pharmacy & Therapeutics, 35(8):469-474, Aug 2010

PMDID: 20844697

"131I-rose bengal therapy in hepatoblastoma patients.",

European Journal of Cancer, 27(5):613-5, May 1991

PMDID: 1647184

White Papers

"PV-10 Moves Forward",

W. Alexander, Jun 2013

Scientific Presentations

"Phase 1b Study of PV-10 and anti-PD-1 in Advanced Cutaneous Melanoma.",

ASCO 2019, Abstract No. 9559, June 2019

"A phase I study of oncolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium: Cohort 1 results.",

ASCO 2019, Abstract No. 4102, June 2019

"Interim results of a Phase 1b/2 study of PV-10 and anti-PD-1 in advanced melanoma",

SMR 2018 Congress, December 2018

"Percutaneous Oncolytic Rose Bengal Disodium for Metastatic Uveal Melanoma Patients with Hepatic Metastases",

SMR 2018 Congress, December 2018

"Patterns of Response for Combination of PV-10 Oncolytic Immunotherapy and Checkpoint Inhibition",

Melanoma Bridge 2018, Poster , November 2018

"A Phase 1 Study of Oncolytic Immunotherapy of Metastatic Neuroendocrine Tumours using Intralesional Rose Bengal Disodium",

ESMO 2018, Abstract No. 1334TIP, October 2018

"Current Clinical Trials with PV-10 (Rose Bengal), The First Small Molecule Oncolytic Immunotherapy,",

8th European Post-Chicago Melanoma/Skin Cancer Meeting, Parallel Session 1, June 2018

"In vitro and xenograft anti-tumor activity, target modulation and drug synergy studies of PV-10 against refractory pediatric solid tumors.",

Journal of Surgical Oncology 2018, 36:15_suppl, 10557-10557, June 2018

"Immune Modulation by Topical PH-10 Aqueous Hydrogel (Rose Bengal Disodium) in Psoriasis Lesions",

8th International Psoriasis from Gene to Clinic Congress, Abstract 115, Poster P013, November 2017

"Preliminary Results of a Phase 1b/2 Study of PV-10 and Pembroluzimab in Stage IV Melanoma",

Society for Melanoma Research 2017 Congress, Presentation P15-1, October 2017

"Intralesional Rose Bengal as an Oncolytic Immunotherapy for Hepatic Tumors",

26th Conference of the Asian Pacific Association for the Study of the Liver (APASL), Shanghai, China, Presentation #PP0530, February 2017

"Percutaneous Rose Bengal as an Oncolytic Immunotherapy for Hepatic Metastases",

CIO (Clinical Interventional Oncology) 2017, Hollywood, FL USA, Abstract #15831, February 2017

"Intralesional Rose Bengal in Melanoma Elicits Tumor Immunity via High Mobility Group Box 1",

Society for Immunotherapy of Cancer 30th Annual Meeting
Journal for Immunotherapy of Cancer 2015, 3(Suppl 2):P408, November 2015

"Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver",

6th Asia-Pacific Primary Liver Cancer Expert Meeting, Abstract #P1-84, July 2015

"Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver",

ESMO 17th World Congress on Gastrointestinal Cancer, Abstract #P-116, July 2015

"Trials in Progress: Intralesional PV-10 vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma"

HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting, Apr 2015

"Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma"

Society for Immunotherapy of Cancer 29th Annual Meeting

Journal for Immunotherapy of Cancer 2014, 2(Suppl 3):P120 doi:10.1186/2051-1426-2-S3-P120, Nov 2014

"Subgroup Efficacy in Patients Receiving Intralesional Rose Bengal to All Existing Melanoma in Phase II Study PV-10-MM-02"

European Society For Medical Oncology, Abstract #1120P, Sep 2014

"Efficacy of intralesional rose bengal in patients receiving injection in all existing melanoma in phase II study PV-10-MM-02"

American Society of Clinical Oncology, Jun 2014

"Locoregional Disease Control in Metastatic Melanoma: Exploratory Analyses From Phase 2 Testing of Intralesional Rose Bengal",

European Cancer Congress 2013, Abstract No. 3.755, Sep 2013

"Rose Bengal - Phototoxicity versus Intrinsic Cytotoxicity"

8th World Congress of Melanoma, Free Communications 4: Melanoma Treatment, Abstract FC-021, Jul 2013

"Intralesional Injection with PV-10 Induces a Systemic Anti-tumor Immune Response in Murine Models of Breast Cancer and Melanoma",

American Association for Cancer Research Annual Meeting, Abstract #1248, Apr 2013

"Combination of PV-10 Immuno-chemoablation and Systemic anti-CTLA-4 Antibody Therapy in Murine Models of Melanoma",

American Association for Cancer Research Annual Meeting, Abstract #4755, Apr 2013

"Generation of an Antitumor Response and Immunity Using a Small Molecule Drug (PV-10)",

Society for Immunotherapy of Cancer 27th Annual Meeting [ poster ]

Journal of Immunotherapy Vol. 35, No. 9, Nov 2012

"Immuno-chemoablation of metastatic melanoma with intralesional rose bengal",

European Society for Medical Oncology 2012 Congress, Oct 2012

"Intralesional Injection of Melanoma with Rose Bengal Induces Regression of Untreated Synchronous Melanoma In a Murine Model",

Society of Surgical Oncology Annual Meeting, Mar 2012

"Chemoablation of Metastatic Melanoma with Rose Bengal (PV-10)"

American Society of Clinical Oncology, Jun 2010

"Chemoablation of Melanoma with Intralesional Rose Bengal (PV-10)"

American Society of Clinical Oncology, Jun 2009

"Rose Bengal induces dual modes of cell death in melanoma cells and has clinical activity against melanoma",

Melanoma Research 16(Suppl 1):S8, Sep 2006

Other Publications ( 27 publications )

"Rose Bengal for melanoma treatment: will it translate to the clinic?",

Melanoma Management, (2015) 2(2):101-103, May 2015

"PV-10 in Advanced Melanoma: High Response Rates, Evidence of Systemic Response",

Cancer Watch, Vol. 22:155-156, Oct 2013

"Rose Bengal-Based Drug Kills Both Primary and Secondary Melanoma Tumors",

Bio Research International, Vol.18 No.5, Sep 2013

"Back to Phase 1: Understanding Systemic Effects of PV-10",

Cancer Watch, Vol. 22:21-23, Feb 2013

"ESMO 2012: PV-10 shows sustained response in melanoma",

ecancer news, Oct 2012

"Immunotherapy Update: Ipilimumab and Intralesional Therapies",

Cancer Watch, Vol. 21:135-136, Sep 2012

"Provectus looks to Phase III with positive melanoma data",

Scrip Intelligence, Jun 2012

"Metastatic Melanoma: A Murine Study Confirming an Immune Response with PV-10",

Cancer Watch, Vol. 21:86-89, Jun 2012

"PV-10, aka Rose Bengal: Intralesional Therapy For Metastatic Melanoma",

The Melanoma Letter, Vol. 30, No. 1:5-7, May 2012

"Rose Bengal - More Than Just a Red Food Dye?",

The North Carolina Osteopathic Medical Association News:25, Mar 2012

"Clinical News",

BioCentury, March 26, 2012

"Individualized Local Treatment Strategies for In-Transit Melanoma",

ONCOLOGY, Feb 2012

"PV-10: A Melanoma Therapeutic in the Pipeline",

Practical Dermatology, January 2012:41-42, Jan 2012

"New Agents Stir Interest in Intralesional Therapy for Cutaneous Metastatic Melanoma",

Cancer Watch, Vol. 20, No. 9:139-140, Sep 2011

"One-year Findings in Metastatic Melanoma Confirm Rose Bengal Benefit",

The Oncology Pharmacist, Vol. 4, No. 1:139-140, Feb 2011

"Slovenian Woman Travels to St. Luke's Cancer Center to Receive Treatment for Advanced Melanoma with Dr. Agarwala",

St. Luke's Cancer Connection Letter, Jan 2011

"Melanoma: Rose bengal scores, ipilimumab sees delay",

Oncology News International, Vol. 19, No. 12:139-140, Dec 2010

"Compassionate Input to Phase III",

Trials In Focus, December 6, 2010

"Chemoablation of Metastatic Melanoma",

Cancer Watch, Vol 19, No. 11:164-164, Nov 2010

"Chemoablation of Metastatic Melanoma with PV-10",

Presentation at 4th Interdisciplinary Melanoma & Skin Cancer Centres Meeting, Sydney, AU, Nov 2010

"Skin cancer tumors busted with red dye 'tattoo' trial",

The Courier-Mail, Nov. 4, 2010

"High Responses in Melanoma for Wool Dye/Ocular Stain Rose Bengal",

The Oncology Pharmacist, Vol. 3 No. 7, Oct 2010

"Rose Bengal: From a Wool Dye to a Cancer Therapy",

Pharmacy and Therapeutics, Vol. 35, No. 8:469-469, Aug 2010

"Trial heralding a new day for melanoma meets with guarded enthusiasm",

Oncology News International, Vol. 19, No. 7, Jul 2010

"Robust Response in Metastatic Melanoma to Rose Bengal (PV-10)",

Cancer Watch, Vol. 19, No. 7:109-110, Jul 2010

"Promising Data on Ipilimumab and Other Investigational Melanoma Therapies",

Practical Dermatology, Vol. 7, No. 6:24-25, Jun 2010

"New era in metastatic melanoma",

Molecular Oncology, Vol. 4, N0. 2:91-97, Apr 2010